Highlights from PAAM Hybrid Conference: Biologics in food allergy
Biologics are a promising class of therapeutics which target the underlying molecular pathways driving food allergy. Dr. Sindher discussed the wealth promising of clinical data demonstrating the use of anti-IgE antibody omalizumab for improving the safety and efficacy of oral immunotherapy as well as its potential use independently of oral immunotherapy. In addition, there are many exciting upcoming biologics that are currently under investigation in ongoing clinical trials such as the next generation anti-IgE antibody ligelizumab, the anti-IL4 receptor alpha antibody dupilumab, and the anti-interleukin 33 antibody etokimab. Ongoing clinical trials are continuing to investigate the promising potential of these biological therapeutics in food allergy.
By Andrew Chin
Andrew Chin is a scientific grant writer at the Sean N. Parker Center who works closely with Drs. Chinthrajah and Sindher to assist with the Center's manuscripts, grants presentations, and other aspects of scientific writing. His background in basic research allows him to bring complementary insights to the clinical research in the Center.
